Side-by-side · Research reference
AHK-CuvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED14/43 cited
BFDA-ApprovedFlagship15/53 cited
AHK-Cu
Tripeptide-Copper Complex · Cosmetic
Topical · Scalp / Skin
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
AHK-Cu
Semaglutide
Primary target
Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
AHK-Cu
Semaglutide
Effective concentration (in vitro)
10⁻¹² – 10⁻⁹ MPyo 2007
Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.
—
Topical formulation
0.001–0.01% (estimated cosmetic range)
No standardized human protocol published — extrapolated from in vitro data.
—
Frequency
Once or twice daily (topical application)
Once weekly, same day each week
Route
Topical — scalp or dermal application
—
Evidence basis
Ex vivo hair follicle / in vitro DPC studiesPyo 2007
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Duration
Not established — cosmetic protocols typically 8–12 weeks
Indefinite for chronic indication
Discontinuation results in weight regain.
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
AHK-Cu
Semaglutide
Local irritation
Mild erythema, pruritus at application site (copper peptide class effect)
—
Copper sensitivity
Rare hypersensitivity reaction in copper-sensitive individuals
—
Systemic absorption
Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses
—
Data limitations
No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
AHK-Cu
- ·Known copper allergy or Wilson's disease
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
AHK-Cu
- ·Broken or inflamed skin (increased absorption risk)
- ·Concurrent use of other copper-containing formulations
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
AHK-Cu
Semaglutide
1. Topical application
Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Frequency
Once or twice daily. Evening application preferred for overnight contact time.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Scalp preparation
For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Room temperature, protected from light. Copper complexes may degrade in UV exposure.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Duration
Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
AHK-Cu
+ GHK-Cu
ModerateBoth tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.
- AHK-Cu
- 0.001–0.01% topical · AM
- GHK-Cu
- 0.001–0.01% topical · PM
- Frequency
- Daily alternation or combined formulation
- Primary benefit
- Comprehensive dermal regeneration, angiogenesis, hair follicle support
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)